Published in
Wiley, British Journal of Dermatology, 4(177), p. 1033-1042, 2017
DOI: 10.1111/bjd.15706
Links
Tools
Secukinumab sustains good efficacy and favourable safety in moderate-to-severe psoriasis after up to 3 years of treatment: results from a double-blind extension study
Journal article published in 2017 by
R. Bissonnette 
,
T. Luger,
D. Thaçi,
D. Toth,
I. Messina,
R. You,
A. Guana,
T. Fox,
C. Papavassilis,
I. Gilloteau,
U. Mrowietz
,
T. Luger,
D. Thaçi,
D. Toth,
I. Messina,
R. You,
A. Guana,
T. Fox,
C. Papavassilis,
I. Gilloteau,
U. Mrowietz
This paper is made freely available by the publisher.
Full text: Download
Published version:
archiving forbidden
Data provided by 